The Business of Fibroids.....

[Guest guest]

BioSphere Medical Reports First Quarter 2004 Financial Results;

Consolidated Revenue Up 4%; Net Loss Decreased 28% from Prior Year period

ROCKLAND, Mass.--(BUSINESS WIRE)--April 29, 2004--BioSphere Medical,

Inc. (Nasdaq: BSMD), a medical device company that is pioneering the

use of bioengineered microspheres to treat uterine fibroids,

hypervascularized tumors and vascular malformations by occluding their

blood supply, today reported its financial results for the first

quarter ended March 31, 2004.

read the rest here:

http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view≠\

wsId=20040429005410&newsLang=en

************************

April 29, 2004 09:00 AM US Eastern Timezone

B. Moll & Associates, Ltd. is Investigating Reports of Serious

Injuries and Deaths Due to Chromium VI Exposure Against Tru-Coat

Plating and Finishing Company, Inc.

CHICAGO--(BUSINESS WIRE)--April 29, 2004-- B. Moll &

Associates, Ltd. announces that it is investigating claims against

Tru-Coat Plating and Finishing Company, Inc. for allowing severe and

dangerous levels of hexavalent chromium ( " Chromium VI " ) to escape into

the atmosphere putting residents of Bellwood, Illinois (just south of

O'Hare International Airport) and the surrounding area at risk for

severe injuries and death.

Exposure to Chromium VI is known to cause lung cancer, liver, heart,

respiratory and reproductive failure as well as cancer of the brain,

kidney, breast, uterus and gastrointestinal system, Hodgkin disease,

frequent miscarriages, death and more. Early symptoms of inhalation

toxicity may include ulcers and holes in the nasal septum.

read the rest here:

http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view≠\

wsId=20040429005214&newsLang=en

*********************

AEterna/Zentaris and Solvay Report Headline Positive Data from Six

Phase II Trials of Cetrorelix in Three Indications: Endometriosis,

Uterine Myomas and Benign Prostatic Hyperplasia

QUEBEC CITY, Canada, April 29 /PRNewswire/ --

- Clinical Phase II data in endometriosis and in pre-surgical

treatment of uterine myomas to be presented at the 18th World Congress

of the International Federation of Fertility Societies (IFFS) on May

23-28, 2004

- All amounts are in Canadian dollars, unless indicated otherwise

AEterna Laboratories Inc. (TSX: AEL; NASDAQ: AELA), along with its

wholly-owned subsidiary Zentaris GmbH, today announced statistically

significant positive results from a recently completed Phase II

clinical program designed to evaluate cetrorelix, a luteinizing

hormone releasing hormone (LHRH) antagonist, in three different

indications: endometriosis, pre-surgical treatment of uterine myomas

and benign prostatic hyperplasia (BPH), that can benefit from a

targeted and controlled decrease in sex hormones, including estrogen

and testosterone. The positive results of six Phase II trials, which

also demonstrated good tolerability in all indications, will form the

basis for further development of cetrorelix in different indications

through collaboration with Solvay Pharmaceuticals, the Company's

worldwide (ex-Japan) exclusive development and marketing partner for

cetrorelix for the above indications.

read the rest here:

http://www.prnewswire.co.uk/cgi/news/release?id=121970

**********************